Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Jun;71(6):1311–1314. doi: 10.1038/bjc.1995.254

Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group.

R de Wit 1, G Stoter 1, D T Sleijfer 1, S B Kaye 1, P H de Mulder 1, W W ten Bokkel Huinink 1, P J Spaander 1, M de Pauw 1, R Sylvester 1
PMCID: PMC2033818  PMID: 7540039

Abstract

We have investigated whether an alternating induction chemotherapy regimen of PVB/BEP is superior to BEP in patients with poor-prognosis testicular non-seminoma. A total of 234 eligible patients were randomised to receive an alternating schedule of PVB/BEP for a total of four cycles or four cycles of BEP. Poor prognosis was defined as any of the following: lymph node metastases larger than 5 cm, lung metastases more than four in number or larger than 2 cm, haematogenic spread outside the lungs, such as in liver and bone, human chorionic gonadotrophin > 10,000 IU l-1 or alphafetoprotein > 1000 IU l-1. The complete response (CR) rates to PVB/BEP and BEP were similar, 76% and 72% respectively (P = 0.58). In addition, there was no significant difference in relapse rate, disease-free and overall survival at an average follow-up of 6 years. The 5-year progression-free and survival rates in both treatment groups were approximately 80%. The PVB/BEP regime was more toxic with regard to bone marrow function; the frequencies of leucocytes below 1000 microliters-1, leucocytopenic fever and platelets below 25,000 microliters-1, throughout four cycles were 28% vs 5% (P < 0.001), 16% vs 5% (P = 0.006), and 10% vs 1% (P = 0.001) respectively. Neuropathy also occurred more often in the PVB/BEP arm: 47% vs 25% (P = 0.001). This study shows that an alternating regimen of PVB/BEP is not superior to BEP and that it is more myelo- and neurotoxic.

Full text

PDF
1311

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bajorin D., Katz A., Chan E., Geller N., Vogelzang N., Bosl G. J. Comparison of criteria for assigning germ cell tumor patients to "good risk" and "poor risk" studies. J Clin Oncol. 1988 May;6(5):786–792. doi: 10.1200/JCO.1988.6.5.786. [DOI] [PubMed] [Google Scholar]
  2. Bosl G. J., Geller N. L., Cirrincione C., Vogelzang N. J., Kennedy B. J., Whitmore W. F., Jr, Vugrin D., Scher H., Nisselbaum J., Golbey R. B. Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res. 1983 Jul;43(7):3403–3407. [PubMed] [Google Scholar]
  3. Bosl G. J., Geller N. L., Vogelzang N. J., Carey R., Auman J., Whitmore W. F., Herr H., Morse M., Sogani P., Chan E. Alternating cycles of etoposide plus cisplatin and VAB-6 in the treatment of poor-risk patients with germ cell tumors. J Clin Oncol. 1987 Mar;5(3):436–440. doi: 10.1200/JCO.1987.5.3.436. [DOI] [PubMed] [Google Scholar]
  4. Bosl G. J., Yagoda A., Golbey R. B., Whitmore W., Jr, Herr H., Sogani P., Morse M., Vogelzang N., MacDonald G. Role of etoposide-based chemotherapy in the treatment of patients with refractory or relapsing germ cell tumors. Am J Med. 1985 Mar;78(3):423–428. doi: 10.1016/0002-9343(85)90333-x. [DOI] [PubMed] [Google Scholar]
  5. Cullen M. H., Harper P. G., Woodroffe C. M., Kirkbride P., Clarke J. Chemotherapy for poor risk germ cell tumours. An independent evaluation of the POMB/ACE regime. Br J Urol. 1988 Nov;62(5):454–460. doi: 10.1111/j.1464-410x.1988.tb04396.x. [DOI] [PubMed] [Google Scholar]
  6. Einhorn L. H. Testicular cancer as a model for a curable neoplasm: The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res. 1981 Sep;41(9 Pt 1):3275–3280. [PubMed] [Google Scholar]
  7. Goldie J. H., Coldman A. J., Gudauskas G. A. Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep. 1982 Mar;66(3):439–449. [PubMed] [Google Scholar]
  8. Goldie J. H., Coldman A. J. The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Cancer Res. 1984 Sep;44(9):3643–3653. [PubMed] [Google Scholar]
  9. Hitchins R. N., Newlands E. S., Smith D. B., Begent R. H., Rustin G. J., Bagshawe K. D. Long-term outcome in patients with germ cell tumours treated with POMB/ACE chemotherapy: comparison of commonly used classification systems of good and poor prognosis. Br J Cancer. 1989 Feb;59(2):236–242. doi: 10.1038/bjc.1989.48. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Horwich A., Brada M., Nicholls J., Jay G., Hendry W. F., Dearnaley D., Peckham M. J. Intensive induction chemotherapy for poor risk non-seminomatous germ cell tumours. Eur J Cancer Clin Oncol. 1989 Feb;25(2):177–184. doi: 10.1016/0277-5379(89)90005-9. [DOI] [PubMed] [Google Scholar]
  11. Lewis C. R., Fossà S. D., Mead G., ten Bokkel Huinink W., Harding M. J., Mill L., Paul J., Jones W. G., Rodenburg C. J., Cantwell B. BOP/VIP--a new platinum-intensive chemotherapy regimen for poor prognosis germ cell tumours. Ann Oncol. 1991 Mar;2(3):203–211. doi: 10.1093/oxfordjournals.annonc.a057906. [DOI] [PubMed] [Google Scholar]
  12. Loehrer P. J., Sr, Williams S. D., Einhorn L. H. Ifosfamide in testicular cancer: the Indiana University experience. Semin Oncol. 1989 Feb;16(1 Suppl 3):96–101. [PubMed] [Google Scholar]
  13. Logothetis C. J., Samuels M. L., Selig D. E., Ogden S., Dexeus F., Swanson D., Johnson D., von Eschenbach A. Cyclic chemotherapy with cyclophosphamide, doxorubicin, and cisplatin plus vinblastine and bleomycin in advanced germinal tumors. Results with 100 patients. Am J Med. 1986 Aug;81(2):219–228. doi: 10.1016/0002-9343(86)90255-x. [DOI] [PubMed] [Google Scholar]
  14. Mead G. M., Stenning S. P., Parkinson M. C., Horwich A., Fossa S. D., Wilkinson P. M., Kaye S. B., Newlands E. S., Cook P. A. The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Medical Research Council Testicular Tumour Working Party. J Clin Oncol. 1992 Jan;10(1):85–94. doi: 10.1200/JCO.1992.10.1.85. [DOI] [PubMed] [Google Scholar]
  15. Ozols R. F., Ihde D. C., Linehan W. M., Jacob J., Ostchega Y., Young R. C. A randomized trial of standard chemotherapy v a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors. J Clin Oncol. 1988 Jun;6(6):1031–1040. doi: 10.1200/JCO.1988.6.6.1031. [DOI] [PubMed] [Google Scholar]
  16. Pastan I., Gottesman M. Multiple-drug resistance in human cancer. N Engl J Med. 1987 May 28;316(22):1388–1393. doi: 10.1056/NEJM198705283162207. [DOI] [PubMed] [Google Scholar]
  17. Stoter G., Bosl G. J., Droz J. P., Fossa S. D., Freedman L. S., Geller N. L., Horwich A., Jones W. G., Kaye S. B., Mead G. M. Prognostic factors in metastatic germ cell tumors. Prog Clin Biol Res. 1990;357:313–319. [PubMed] [Google Scholar]
  18. Stoter G., Koopman A., Vendrik C. P., Struyvenberg A., Sleyfer D. T., Willemse P. H., Schraffordt Koops H., van Oosterom A. T., ten Bokkel Huinink W. W., Pinedo H. M. Ten-year survival and late sequelae in testicular cancer patients treated with cisplatin, vinblastine, and bleomycin. J Clin Oncol. 1989 Aug;7(8):1099–1104. doi: 10.1200/JCO.1989.7.8.1099. [DOI] [PubMed] [Google Scholar]
  19. Stoter G., Sleyfer D. T., ten Bokkel Huinink W. W., Kaye S. B., Jones W. G., van Oosterom A. T., Vendrik C. P., Spaander P., de Pauw M., Sylvester R. High-dose versus low-dose vinblastine in cisplatin-vinblastine-bleomycin combination chemotherapy of non-seminomatous testicular cancer: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. J Clin Oncol. 1986 Aug;4(8):1199–1206. doi: 10.1200/JCO.1986.4.8.1199. [DOI] [PubMed] [Google Scholar]
  20. Stoter G., Sylvester R., Sleijfer D. T., ten Bokkel Huinink W. W., Kaye S. B., Jones W. G., van Oosterom A. T., Vendrik C. P., Spaander P., de Pauw M. Multivariate analysis of prognostic factors in patients with disseminated nonseminomatous testicular cancer: results from a European Organization for Research on Treatment of Cancer Multiinstitutional Phase III Study. Cancer Res. 1987 May 15;47(10):2714–2718. [PubMed] [Google Scholar]
  21. Williams S. D., Birch R., Einhorn L. H., Irwin L., Greco F. A., Loehrer P. J. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med. 1987 Jun 4;316(23):1435–1440. doi: 10.1056/NEJM198706043162302. [DOI] [PubMed] [Google Scholar]
  22. Williams S. D., Einhorn L. H., Greco F. A., Oldham R., Fletcher R. VP-16-213 salvage therapy for refractory germinal neoplasms. Cancer. 1980 Nov 15;46(10):2154–2158. doi: 10.1002/1097-0142(19801115)46:10<2154::aid-cncr2820461008>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES